Bayer’s Dermatology Unit Sale Said to Attract Teva and Perrigo

  • Buyout firms including Nordic, KKR, Bain may also weigh bids
  • Initial offers for the assets are due in the coming weeks

Bayer AG’s dermatology unit is attracting interest from a number of health-care and private equity firms as the German company seeks to raise cash for its $66 billion acquisition of Monsanto Co., according to people with knowledge of the matter.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.